Lower middle market healthcare private equity firm

3 Boomerang Capital

  • HeadquartersGreenwich, CT S6
  • Website3boomerang.com
  • Last verifiedOctober 28, 2026

At a glance

Latest fund3 Boomerang Capital I, LP, $376M (Feb 2024) S7
EBITDA range$4M to $14M S3
Deal typesPlatform, Add-on, Minority, Growth S3
GeographyNorth America, Western Europe S3
SectorsHealthcare Services, Industrial & Manufacturing, Accounting & Professional Services

What 3 Boomerang Capital buys

3 Boomerang Capital is a Greenwich, Connecticut private equity firm that invests only in healthcare. It works in four corners of the industry: outsourced services for drug and biotech companies, contract manufacturing for medical devices and diagnostics, healthcare IT and tech-enabled services, and care delivered outside the hospital. The target is a company owned by its founder or family, or a division a larger company wants to sell, with roughly $4 million to $14 million of EBITDA and a base in North America or Western Europe.

The firm invests from its first fund, a $376 million vehicle that closed in early 2024. It will take control or a minority stake, and it puts money to work through recapitalizations that give owners some cash, growth projects, management buyouts and acquisitions. Since 2024 it has backed ABS Bio, Enjoin, Bio-Response Solutions, Matrix Plastic Products and a life sciences consulting platform now called Pinnaql. Three of those have already bought smaller companies, so a business below the EBITDA range is most likely to meet 3 Boomerang as a tuck-in.

Recent deals

Announced in the 24 months before October 28, 2026.

DateCompanyTypeSectorSource
Apr 2026Pharma Resource GroupAnalytical science, formulation and manufacturing advisory firm added to Pinnaql, its third tuck-in in about 10 monthsAdd-onAccounting & Professional ServicesSource
Jan 2026CurelineFounder-built biospecimen and histology provider in South San Francisco added to ABS BioAdd-onHealthcare ServicesSource
Dec 2025Pediatric Resource GroupPediatric clinical documentation and physician advisory firm added to EnjoinAdd-onHealthcare ServicesSource
Aug 2025Validation & Engineering GroupPuerto Rico based commissioning, qualification and validation services firm added to PinnaqlAdd-onAccounting & Professional ServicesSource
Jun 2025PinnaqlLab validation and compliance firm bought as the first acquisition of LSOMS Holdings, which now operates under the Pinnaql nameAdd-onAccounting & Professional ServicesSource
Jun 2025Matrix Plastic ProductsPrecision injection molder for medical devices and robotic surgery; the CEO stays on in Wood Dale, IllinoisPlatformIndustrial & ManufacturingSource
Jun 2025LSOMS HoldingsNew quality and regulatory consulting platform for life sciences companies, built with an industry executivePlatformAccounting & Professional ServicesSource
Mar 2025Bio-Response SolutionsIndiana maker of alkaline hydrolysis and sterilization equipment; growth investmentPlatformIndustrial & ManufacturingSource
Nov 2024EnjoinMajority growth recapitalization of a clinical documentation services provider to hospitals, founded in 1988PlatformHealthcare ServicesSource

Portfolio by sector

From the firm's portfolio page S4.

Biopharma Outsourcing

  • ABS Bio
  • Pinnaql

Information Technology & Tech Enabled Services

  • Enjoin

Medical Device & Diagnostic Manufacturing

  • Matrix Plastic Products
  • Bio-Response Solutions

Greymont’s take

How 3 Boomerang Capital fits a seller

3 Boomerang suits the owner of a healthcare business that sells to hospitals, drug makers or device companies and wants a partner that knows that world well. Its deals so far have mostly been recapitalizations where the existing leaders keep running the company. Enjoin's CEO stayed in place after the 2024 deal, and Matrix's CEO kept leading the business from its Illinois base. The firm also brings in outside executives as a company grows, as it did when Pinnaql named a new CEO in September 2026.

Owners of smaller firms in clinical documentation, biospecimens or life sciences consulting should expect the talk to be about joining Enjoin, ABS Bio or Pinnaql rather than becoming a new platform. Good questions to ask are whether the firm wants control or a minority stake in your case, and how much of your equity it expects you to roll into the combined company.

Questions owners ask

What size company does 3 Boomerang Capital look for?

Its stated target is a lower middle market healthcare company with about $4 million to $14 million of EBITDA, owned by its founder or being sold by a larger corporation, and based in North America or Western Europe.

Does 3 Boomerang take minority stakes?

Yes. It says it can invest for control or for a minority position, and it lists recapitalizations that give shareholders some liquidity, growth capital, acquisitions and management buyouts among the ways it puts money to work.

Which parts of healthcare does 3 Boomerang invest in?

Four areas: outsourced services for biopharma companies, medical device and diagnostic manufacturing, healthcare information technology and tech-enabled services, and alternate site care, meaning care delivered outside the hospital.

How much capital does 3 Boomerang have to invest?

It invests from 3 Boomerang Capital I, LP, a $376 million fund. The firm's news page shows that fund closing above its target in February 2024, and its first platform deal came that June.

Sources

  1. S13 Boomerang Capital home page Accessed October 28, 2026
  2. S23 Boomerang Capital: About Accessed October 28, 2026
  3. S33 Boomerang Capital: Investment Focus Accessed October 28, 2026
  4. S43 Boomerang Capital: Portfolio Accessed October 28, 2026
  5. S53 Boomerang Capital: News Accessed October 28, 2026
  6. S63 Boomerang Capital Announces Growth Recapitalization of Enjoin (PR Newswire, November 21, 2024) Accessed October 28, 2026
  7. S7Pinnaql Names Allison Kerska CEO (PR Newswire, September 15, 2026) Accessed October 28, 2026
  8. S83 Boomerang Capital Makes Investment in Matrix Plastic Products (PR Newswire, June 10, 2025) Accessed October 28, 2026
  9. S9Enjoin Acquires Pediatric Resource Group (PR Newswire, December 16, 2025) Accessed October 28, 2026

Compiled by Greymont Advisors from public sources, including the firm’s own website and press releases. Greymont is not affiliated with 3 Boomerang Capital. Figures are as reported on the dates shown and may have changed. Request a correction

For business owners

Thinking about selling? Talk to Greymont.

We work for the buyers, so owners never pay us a fee or a share of proceeds. Find out how ready your business is in four minutes, or start a confidential conversation.

Take the Readiness Scorecard Start a Conversation